Pharma News
Phosphagenics Licenses Diclofenac Gel for Indian Market
Phosphagenics Licenses Diclofenac Gel for Indian Market 2 November 2011, Melbourne, Australia: Melbourne drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), has licensed TPM/diclofenac, its topical non-steroidal pain formulation, to Themis Medicare Pvt Ltd of Mumbai for the Indian market. This represents Phosphagenics’ first commercial deal in India and its first licensing agreement of its diclofenac product. Under the terms of the agreement, Themis Medicare is committed to pay Phosphagenics an undisclosed up-front fee and double-digit royalty payments on sales. Themis Medicare is an Indian company that manufactures, formulates and markets...
Read MoreParacetamol combination drugs to carry warnings
Manufacturer of paracetamol combination products will now have to print a statutory warning on the drug boxes stating ‘Taking more than the daily dose of paracetamol may cause serious liver damage or allergic reactions’. Besides, the Drug Controller General of India (DCGI) has asked the state licensing authorities not to grant fresh licenses or renewals to products with combination of paracetamol, containing more than 325 mg per tablet or capsule. The decision of limiting acetaminophen (paracetamol) comes in the wake of the US FDA issuing a similar note on January 13, 2011. “Manufacturers marketing combination products having more than 325 mg of paracetamol have...
Read More